Four individually druggable MET hotspots mediate HGF-driven tumor progression

Journal of Clinical Investigation

Volumn 124, Issue 7, 2014, Pages 3172-3186

  Basilico, Cristina ^a,b   Hultberg, Anna ^c   Blanchetot, Christophe ^c   De Jonge, Natalie ^c   Festjens, Els ^c   Hanssens, Valérie ^c   Osepa, Sjudry Ilona ^c   De Boeck, Gitte ^c   Mira, Alessia ^a   Cazzanti, Manuela ^a,b   Morello, Virginia ^a,b   Dreier, Torsten ^c   Saunders, Michael ^c   De Haard, Hans ^c   Michieli, Paolo ^a,b  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c ArGEN X BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETASTATIC AGENT; CHIMERIC ANTIBODY; CHIMERIC MONOCLONAL ANTIBODY WT14; CHIMERIC MONOCLONAL ANTIBODY WT15; CHIMERIC MONOCLONAL ANTIBODY WT25; CHIMERIC MONOCLONAL ANTIBODY WT26; CHIMERIC MONOCLONAL ANTIBODY WT3; CHIMERIC MONOCLONAL ANTIBODY WT37; CHIMERIC MONOCLONAL ANTIBODY WT38; CHIMERIC MONOCLONAL ANTIBODY WT4; CHIMERIC MONOCLONAL ANTIBODY WT46; CHIMERIC MONOCLONAL ANTIBODY WT5; CHIMERIC MONOCLONAL ANTIBODY WT52; CHIMERIC MONOCLONAL ANTIBODY WT53; CHIMERIC MONOCLONAL ANTIBODY WT60; IMMUNOGLOBULIN G1; JNJ 38877605; K RAS PROTEIN; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ALPHA CHAIN; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY COMBINING SITE; ANTIGEN BINDING; ARTICLE; BETA CHAIN; BIOASSAY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL ASSAY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; LIVER METASTASIS; METASTASIS INHIBITION; METASTATIC COLORECTAL CANCER; MONOTHERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR INVASION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; BINDING SITES; BINDING, COMPETITIVE; BRAIN NEOPLASMS; CAMELIDS, NEW WORLD; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GLIOBLASTOMA; HEPATOCYTE GROWTH FACTOR; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MODELS, MOLECULAR; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTO-ONCOGENE PROTEINS C-MET;

EID: 84903785242     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI72316     Document Type: Article

References (52)

1. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer. 2006;6(8):637-645.
2. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4(12):915-925.
3. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008;7(6):504-516.
4. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003;3(4):347-361.
5. Steffan JJ, Coleman DT, Cardelli JA. The HGF-met signaling axis: emerging themes and targets of inhibition. Curr Protein Pept Sci. 2011;12(1):12-22.
6. Seol DW, Chen Q, Zarnegar R. Transcriptional activation of the hepatocyte growth factor receptor (c-met) gene by its ligand (hepatocyte growth factor) is mediated through AP-1. Oncogene. 2000;19(9):1132-1137.
7. Jahangiri A, et al. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res. 2013;19(7):1773-1783.
8. Qian LW, et al. Radiation stimulates HGF receptor/ c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells. Int J Cancer. 2003; 104(5):542-549.
9. Engelman JA, Jänne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 2008;14(10):2895-2899.
10. Lyon M, Deakin JA, Mizuno K, Nakamura T, Gallagher JT. Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J Biol Chem. 1994;269(15):11216-11223.
11. Smolen GA, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A. 2006;103(7):2316-2321.
12. Lutterbach B, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 2007; 67(5):2081-2088.
13. Turke AB, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010;17(1):77-88.
14. Linehan WM, et al. Identification of the genes for kidney cancer: opportunity for diseasespecific targeted therapeutics. Clin Cancer Res. 2007;3(2 pt 2):671s-679s.
15. Michieli P, et al. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene. 1999;18(37):5221-5231.
16. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer. 2002;2(4):289-300.
17. Naldini L, et al. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J. 1992; 11(13):4825-4833.
18. Kirchhofer D, et al. Structural and functional basis of the serine protease-like hepatocyte growth factor β-chain in Met binding and signaling. J Biol Chem. 2004;279(38):39915-39924.
19. Matsumoto K, Kataoka H, Date K, Nakamura T. Cooperative interaction between α-and β-chains of hepatocyte growth factor on c-Met receptor confers ligand-induced receptor tyrosine phosphorylation and multiple biological responses. J Biol Chem. 1998;273(36):22913-22920.
20. Stamos J, Lazarus RA, Yao X, Kirchhofer D, Wiesmann C. Crystal structure of the HGF β-chain in complex with the Sema domain of the Met receptor. EMBO J. 2004;23(12):2325-2335.
21. Merchant M, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci USA. 2013;110(32):E2987-E2996.
22. Basilico C, Arnesano A, Galluzzo M, Comoglio PM, Michieli P. A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J Biol Chem. 2008;283(30):21267-21277.
23. Yokozaki H. Molecular characteristics of eight gastric cancer cell lines established in Japan. Pathol Int. 2000;50(10):767-777.
24. de Haard HJ, et al. Llama antibodies against a lactococcal protein located at the tip of the phage tail prevent phage infection. J Bacteriol. 2005; 187(13):4531-4541.
25. de Haard HJ, et al. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem. 1999;274(26):18218-18230.
26. Jin H, et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 2008; 68(11):4360-4368.
27. Goetsch L, inventor; Pierre Fabre Medicament, assignee. Antibodies inhibiting c-Met dimerization uses thereof. US patent 20130273060 A1. July 10, 2008.
28. Michieli P, et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell. 2004;6(1):61-73.
29. Pacchiana G, et al. Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. J Biol Chem. 2010;285(46):36149-36157.
30. Martens T, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res. 2006;12(20 pt 1):6144-6152.
31. Chan GK, Lutterbach BA, Pan BS, Kariv I, Szewczak AA. High-throughput analysis of HGF-stimulated cell scattering. J Biomol Screen. 2008;13(9):847-854.
32. Rong S, et al. Tumorigenesis induced by coexpression of human hepatocyte growth factor and the human met protooncogene leads to high levels of expression of the ligand and receptor. Cell Growth Differ. 1993;4(7):563-569.
33. Maggiora P, et al. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res. 2003;288(2):382-389.
34. Tyan SW, et al. Breast cancer cells induce cancerassociated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis. PLoS One. 2011;6(1):e15313.
35. Mueller KL, Madden JM, Zoratti GL, Kuperwasser C, List K, Boerner JL. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Breast Cancer Res. 2012;14(4):R104.
36. Kuperwasser C, et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A. 2004;101(14):4966-4971.
37. De Bacco F, et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst. 2011; 103(8):645-661.
38. Galimi F, et al. Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to MET inhibition in patient xenografts and pathologic correlations. Clin Cancer Res. 2011;17(10):3146-3156.
39. Vermeulen L, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010;12(5):468-476.
40. Koliaraki V, Roulis M, Kollias G. Tpl2 regulates intestinal myofibroblast HGF release to suppress colitis-associated tumorigenesis. J Clin Invest. 2012; 122(11):4231-4242.
41. Céspedes MV, et al. Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. Am J Pathol. 2007;170(3):1077-1085.
42. Niemann HH, et al. Structure of the human receptor tyrosine kinase met in complex with the Listeria invasion protein InlB. Cell. 2007;130(2):235-246.
43. Takahashi T, Strittmatter SM. Plexin A1 autoinhibition by the plexin sema domain. Neuron. 2001; 29(2):429-439.
44. Prat M, Crepaldi T, Pennacchietti S, Bussolino F, Comoglio PM. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci. 1998;111(pt 2):237-247.
45. Rath P, et al. In vivo c-Met pathway inhibition depletes human glioma xenografts of tumor-propagating stem-like cells. Transl Oncol. 2013;6(2):104-111.
46. De Bacco F, et al. The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res. 2012;72(17):4537-4550.
47. Xie Q, et al. Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci U S A. 2012; 109(2):570-575.
48. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol. 2005; 23(10):2411-2422.
49. Webb CP, et al. Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis. Oncogene. 1998;17(16):2019-2025.
50. Furge KA, et al. Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc Natl Acad Sci U S A. 2001;98(19):10722-10727.
51. de Rock E, Taylor N. An easy method of layering blood over Ficoll-Paque gradients. J Immunol Methods. 1977;17(3-4):373-374.
52. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanatephenol-chloroform extraction. Anal Biochem. 1987; 162(1):156-159.